6 news items
Arcus Biosciences Completes Patient Enrollment in Phase 3 Trial Evaluating a Domvanalimab-Containing Regimen in First-Line Metastatic Upper GI Cancers
RCUS
10 Jun 24
made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the statements
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
GILD
RCUS
2 Jun 24
to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the statements in Dr. Wainberg quote
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
GILD
RCUS
2 Jun 24
of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
GILD
RCUS
1 Jun 24
to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the statements in Dr. Janjigian's
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
GILD
RCUS
1 Jun 24
Securities Litigation Reform Act of 1995, including, but not limited to, the statements in Dr. Janjigian's quote and statements regarding: whether data
fc3q4j32hksgtdesni
RCUS
8 May 24
of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited
- Prev
- 1
- Next